Adjuvant synergy: The effects of nasal coadministration of adjuvants

Immunology and Cell Biology

Volumn 82, Issue 6, 2004, Pages 628-637

  Moschos, S A ^a   Bramwell, V W ^a   Somavarapu, S ^a   Alpar, H O ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Adjuvant; Chitosan; Cholera toxin subunit B; Cytokine; Helicobacter pylori; Mucosal immunization; Muramyl di peptide; Nasal immunization; Vaccine

Indexed keywords

ANTIGEN; BACTERIAL ANTIGEN; CHITOSAN; CHOLERA TOXIN B SUBUNIT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; MURAMYL DIPEPTIDE; PEPTIDE; PROTEIN SUBUNIT; RECOMBINANT ANTIGEN; RECOMBINANT HELICOBACTER PYLORI ANTIGEN; UNCLASSIFIED DRUG; UREASE; VACCINE;

ADOLESCENT; ANIMAL CELL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ANTIGENICITY; ARTICLE; CELL CULTURE; CELLULAR IMMUNITY; DRUG FORMULATION; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; INTRANASAL DRUG ADMINISTRATION; KINETICS; MOUSE; MUCOSAL IMMUNITY; MUCOSAL IMMUNIZATION; NASAL IMMUNIZATION; NONHUMAN; SPLEEN CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CHITOSAN; COMPLEMENT HEMOLYTIC ACTIVITY ASSAY; CYTOKINES; FEMALE; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; KINETICS; MICE; MICE, INBRED BALB C; SPLEEN;

ANIMALIA; BACTERIA (MICROORGANISMS); HELICOBACTER PYLORI;

EID: 9544222615     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0818-9641.2004.01280.x     Document Type: Article

References (82)

1. Almeida AJ, Alpar HO. Nasal delivery of vaccines. J. Drug Target. 1996; 3: 455-67.
2. Alpar HO, Bramwell VW. Current status of DNA vaccines and their route of administration. Crit. Rev. Ther. Drug Carrier Syst. 2002; 19: 307-83.
3. Ott G, Barchfeld GL, Van Nest G. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 1995; 13: 1557-62.
4. Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev. Vaccines 2003; 2: 197-203.
5. Graham BS, Keefer MC, McElrath MJ et al. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Ann. Intern. Med. 1996; 125: 270-9.
6. Verschoor EJ, Mooij P, Oostermeijer H et al. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-for-mulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance. J. Virol. 1999; 73: 3292-300.
7. Del Giudice G, Podda A, Rappuoli R. What are the limits of adjuvanticity? Vaccine 2002; 20: S38-41.
8. Stevceva L, Strober W. Mucosal HIV vaccines: where are we now? Curr. HIV Res. 2004; 2: 1-10.
9. Holmgren J, Czerkinsky C, Eriksson K, Mharandi A. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 2003; 21: S89-S95.
10. Hedlund J, Langer B, Konradsen HB, Ortqvist A. Negligible adjuvant effect for antibody responses and frequent adverse events associated with IL-12 treatment in humans vaccinated with pneumococcal polysaccharide. Vaccine 2001; 20: 164-9.
11. Huber VC, Arulanandam BP, Arnaboldi PM et al. Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int. Immunopharmacol. 2003; 3: 801-9.
12. Baudner BC, Giuliani MM, Verhoef JC, Rappuoli R, Junginger HE, Giudice GD. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine 2003; 21: 3837-44.
13. Artursson P, Lindmark T, Davis SS, Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 1994; 11: 1358-61.
14. Kotze AF, Thanou MM, Luessen HL, De Boer AG, Verhoef JC, Junginger HE. Enhancement of paracellular drug transport with highly quaternized N-trimethyl chitosan chloride in neutral environments: In vitro evaluation in intestinal epithelial (cells Caco-2). J. Pharm. Sci. 1999; 88: 253-7.
15. Thanou MM, Verhoef JC, Romeijn SG, Nagelkerke JF, Merkus FWHM, Junginger HE. Effects of N-trimethyl chitosan chloride, a novel absorption enhancer, on Caco-2 intestinal epithelia and ciliary beat frequency. Int. J. Pharm. 1999; 185: 73-82.
16. Soane RJ, Hinchcliffe M, Davis SS, Illum L. Clearance characteristics of chitosan based formulations in the sheep nasal cavity. Int. J. Pharm. 2001; 217: 183-91.
17. Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int. J. Pharm. 1999; 178: 55-65.
18. Brooking J, Davis SS, Illum L. Transport of nanoparticles across the rat nasal mucosa. J. Drug. Target. 2001; 9: 267-79.
19. Davis SS, Illum L. Absorption enhancers for nasal drug delivery. Clin. Pharmacokin. 2003; 42: 1107-28.
20. Smith RE, Donachie AM, Grdic D, Lycke N, Mowat AM. Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses. J. Immunol. 1999; 162: 5536-46.
21. Chandy T, Wilson RF, Rao GH, Das GS. Changes in eisplatin delivery due to surface-coated poly (lactic acid) -poly (epsilon-caprolactone) microspheres. J. Biomater. Appl. 2002; 16: 275-91.
22. Singh J, Somavarapu S, Alpar HO. PLGA-PCL-co-polymer nanoparticles as a vaccine delivery system. J. Pharm. Pharmacol. 2003; 55: 133.
23. Im SY, Cho SH, Hwang JH, Lee SJ. Growth factor releasing porous poly (epsilon-caprolactone)-chitosan matrices for enhanced bone regenerative therapy. Arch. Pharm. Res. 2003; 26: 76-82.
24. Williamson ED, Sharp GJ, Eley SM et al. Local and systemic immune response to a microencapsulated sub-unit vaccine for plague. Vaccine 1996; 14: 1613-19.
25. Jabbal-Gill I, Fisher AN, Rappuoli R, Davis SS, Illum L. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice. Vaccine 1998; 16: 2039-46.
26. Illum L. Nasal drug delivery - possibilities, problems and solutions. J. Control. Release 2003; 87: 187-98.
27. Mills KH, Cosgrove C, McNeela EA et al. Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a. Infect. Immun. 2003; 71: 726-32.
28. Illum L, Jabbal-Gill I, Hincheliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev. 2001; 51: 81-96.
29. McNeela EA, O'Connor D, Jabbal-Gill I et al. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 2000; 19: 1188-98.
30. Weltzin R, Guy B, Thomas WD, Giannasca PJ, Monath TP. Parenteral activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect. Immun. 2000; 68: 2775-82.
31. Kanellos TS, Byarugaba DK, Russell PH, Howard CR, Partidos CD. Naked DNA when co-administered intranasally with heat-labile enterotoxin of Escherichia coli primes effectively for systemic B- and T-cell responses to the encoded antigen. Immunol. Lett. 2000; 74: 215-20.
32. Isaka M, Yasuda Y, Kozuka S et al. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant. Vaccine 2000; 18: 743-51.
33. Isaka M, Yasuda Y, Mizokami M et al. Mucosal immunization against hepatitis B virus by intranasal co-administration of recombinant hepatitis B surface antigen and recombinant cholera toxin B subunit as an adjuvant. Vaccine 2001; 19: 1460-6.
34. McCluskie MJ, Davis HL. Mucosal immunisation with DNA vaccines. Microbes Infect. 1999; 1: 685-98.
35. Pizza M, Giuliani MM, Fontana MR et al. Mucosal vaccines: non-toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 2001; 19: 2534-41.
36. Lemere CA, Spooner ET, Leverone JF, Mori C, Clements JD. Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT (R192G) as mucosal adjuvants. Neurobiol. Aging 2002; 23: 991-1000.
37. Fujihashi K, Koga T, van Ginkel FW, Hagiwara Y, McGhee JR. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002; 20: 2431-8.
38. Petrovska L, Lopes L, Simmons CP, Pizza M, Dougan G, Chain BM. Modulation of dendritic cell endocytosis and antigen processing pathways by Escherichia coli heat-labile enterotoxin and mutant derivatives. Vaccine 2003; 21: 1445-54.
39. Cong Y, Weaver T, Elson CO. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression. J. Immunol. 1997; 159:5301-8.
40. Marinaro M, Staats HF, Hiroi T et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 1995; 155: 4621-9.
41. Gagliardi M, Sallusto F, Marinaro M, Vendetti S, Riccomi A, De Magistris M. Effects of the adjuvant cholera toxin on dendritic cells: stimulatory and inhibitory signals that result in the amplification of immune responses, Int. J. Med. Microbiol. 2002; 291: 571-5.
42. Braun MC, He J, Wu CY, Kelsall BL. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor betal and beta2 chain expression. J. Exp. Med. 1999; 189: 541-52.
43. Banerjee S, Medina-Fatimi A, Nichols R et al. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut 2002; 51: 634-40.
44. Falnes PØ, Sandvig K. Penetration of protein toxins into cells. Curr. Opin. Cell Biol. 2002; 12: 407-13.
45. Plant A, Williams R, Jackson ME, Williams NA. The B subunit of Escherichia coli heat labile enterotoxin abrogates oral tolerance, promoting predominantly Th2-type immune responses. Eur. J. Immunol. 2003; 33: 3186-95.
46. Alpar HO, Eyles JE, Williamson ED, Somavarapu S. Intranasal vaccination against plague, tetanus and diphtheria. Adv. Drug Deliv. Rev. 2001; 51: 173-201.
47. Sun JB, Stadecker MJ, Mielcarek N. Nasal administration of Schistosoma mansoni egg antigen-cholera B subunit conjugate suppresses hepatic granuloma formation and reduces mortality in S. mansoni-infected mice. Scand. J. Immunol. 2001; 54: 440-7.
48. Ruiz-Bustos E, Sierra-Beltran A, Romero MJ, Rodriguez-Jaramillo C, Ascencio F. Protection of BALB/c mice against experimental Helicobacter pylori infection by oral immunisation with H. pylori heparan sulphate-binding proteins coupled to cholera toxin beta-subunit. J. Med. Microbiol. 2000; 49: 535-41.
49. van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 2000; 165: 4778-82.
50. Peppoloni S, Ruggiero P, Contorni M et al. Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Rev. Vaccines 2003; 2: 285-93.
51. Eriksson K, Holmgren J. Recent advances in mucosal vaccines and adjuvants. Curr. Opin. Immunol. 2002; 14: 666-72.
52. Bagley KC, Abdelwahab SF, Tuskan RG, Lewis GK. An enzymatically active a domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants. Infect. Immun. 2003; 71: 6850-6.
53. Ellouz F, Adam A, Ciobaru R, Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biockem. Biophys. Res. Commun. 1974; 59: 1317-25.
54. Fukushima A, Yoo YC, Yoshimatsu K et al. Effect of MDP-Lys (L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus. Vaccine 1996; 14: 485-91.
55. Allison A. Squalene and squalane emulsions as Adjuvants. Methods 1999; 19: 87-93.
56. Zunic M, Kricek F, Dukor P, Bahr GM. Oral administration of muramyl dipeptide into mice modulates cell proliferation, immunoglobulin synthesis, and cytokine mRNA levels in gut associated lymphoid tissues, Int. J. Immunopharmacol. 1996; 18: 155-62.
57. Keefer MC, Wolff M, Gorse GJ et al. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses 1997; 13: 1163-77.
58. Becker PD, Corral RS, Guzman CA, Grinstein S. Adamantylamide dipeptide as effective immunoadjuvant in rabbits and mice. Vaccine 2001; 19: 4603-9.
59. Fast DJ, Vosika GJ. The muramyl dipeptide analog GMTP-N-MDP preferentially induces cellular immunity to soluble antigens. Vaccine 1997; 15: 1748-52.
60. Whary MT, Palley LS, Batchelder M et al. Promotion of ulcerative duodenitis in young ferrets by oral immunization with Helicobacter mustelae and muramyl dipeptide. Helicobacter 1997; 2: 65-77.
61. Yoo YC, Yoshimatsu K, Koike Y et al. Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine. Vaccine 1998; 16: 216-24.
62. Hoebe K, Janssen EM, Kim SO et al. Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways. Nat. Immunol. 2003; 4: 1223-9.
63. Kaisho T, Akira S. Dendritic-cell function in toll-like receptor-and MyD88-knockout mice. Trends Immunol. 2001; 22: 78.
64. Seya T, Akazawa T, Uehori J, Matsumoto M, Azuma I, Toyoshima K. Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res. 2003; 23: 4369-76.
65. Inohara N, Nuñez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat. Rev. Immunol. 2003; 3: 371-82.
66. Fedorocko P, Hoferova Z, Hofer M, Brezani P. Administration of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and diclofenac in the combination attenuates their anti-tumor activities. Neoplasma 2003; 50: 176-84.
67. Koike Y, Yoo YC, Mitobe M et al. Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant hepatitis B virus vaccine. Vaccine 1998; 16: 1982-9.
68. Puri N, Sinko PJ. Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres II. In vivo investigation. J. Control. Release 2000; 69: 69-80.
69. Zhao Z, Leong KW. Controlled delivery of antigens and adjuvants in vaccine development. J. Pharm. Sci. 1996; 85: 1261-70.
70. Guy B, Hessler C, Fourage S, Rokbi B, Millet MJ. Comparison between targeted and untargeted systemic immunizations with adjuvanted urease to cure Helicobacter pylori infection in mice. Vaccine 1999; 17: 1130-5.
71. Moschos S, Somavarapu S, Singh J et al. Immunogenicity of adjuvanted recombinant urease administered intranasally. Proc. Int. Symp. Controlled Release Bioactive Mater. 2001 ; 28: 1111-12.
72. Eyles JE, Bramwell VW, Singh J, Williamson ED, Alpar HO. Stimulation of spleen cells in vitro by nanospheric particles containing antigen. J. Control. Release 2003; 86: 25-32.
73. Alegre ML, Shiels H, Thompson CB, Gajewski TF. Expression and function of CTLA-4 in Th1 and Th2 cells. J. Immunol. 1998; 161: 3347-56.
74. Beagley KW, Eldridge JH, Lee F et al. Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. J. Exp. Med. 1989; 169: 2133-48.
75. Ramsay AJ, Husband AJ, Ramshaw IA et al. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 1994; 264: 561-3.
76. Kleanthous H, Myers GA, Georgakopoulos KM et al. Rectal and intranasal immunisations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect. Immun. 1998; 66: 2879-86.
77. Cui Z, Mumper RJ. The effect of co-administration of adjuvants with a nanoparticle-based genetic vaccine delivery system on the resulting immune responses. Eur. J. Pharm. Biopharm. 2003; 55: 11-18.
78. O'Garra A. Cytokines Induce the Development of Functionally Heterogeneous T Helper Cell Subsets. Immunity 1998; 8: 755-8.
79. Garhart CA, Heinzel FP, Czinn SJ, Nedrud JG. Vaccine-induced reduction of Helicobacter pylori colonization in mice is interleukin-12 dependent but gamma interferon and inducible nitric oxide synthase independent. Infect. Immun. 2003; 71: 910-21.
80. Akhiani AA, Pappo J, Kabok Z et al. Protection against Helicobacter pylori infection following immunization is IL-12-dependent and mediated by Th1 cells. J. Immunol. 2002; 169: 6977-84.
81. Barr IG, Sjolander A, Cox JC. ISCOM's and other saponin based adjuvants. Adv. Drug Deliv. Rev. 1998; 32: 247-71.
82. Zhang Y, Palmer GH, Abbott JR, Howard CJ, Hope JC, Brown WC. CpG ODN 2006 and IL-12 are comparable for priming Th1 lymphocyte and IgG responses in cattle immunized with a rickettsial outer membrane protein in alum. Vaccine 2003; 21: 3307-18.